Ex parte GANTE et al. - Page 7


                 Appeal No.  2000-0600                                                           Page 7                   
                 Application No.  08/642,268                                                                              
                                The [e]xaminer’s Answer alleges that the assays disclosed in                              
                         the specification and the examples in the art of record (e.g., Muller)                           
                         are only art-recognized for, at best, the treatment of platelet                                  
                         aggregation and thrombosis (as is recited, e.g., in cla[i]m 8).                                  
                         However, the [e]xaminer has provided no reasons to cast doubt on                                 
                         appellants’ assertion that these models are, in fact, suitable for                               
                         determining how to treat the diseases encompassed by the claims                                  
                         (e.g., thromboses, osteolytic disorders, kidney failure, tumors).  As                            
                         was discussed in the Appeal Brief, the burden lies with the [e]xaminer                           
                         to provide evidence which raises doubt about what applicants have                                
                         disclosed as to the utility of the invention (In re Marzochi et al[.]), and in                   
                         the absence of such evidence, the rejection cannot be maintained.                                
                         Here again we find no analysis of the Wands factors by the examiner.                             
                 Instead, we find only the examiner’s unsupported conclusions as to why the                               
                 specification does not enable the claimed invention.  As set forth above, in the                         
                 absence of a fact-based statement of a rejection based upon the relevant legal                           
                 standards, the examiner has not sustained her initial burden of establishing a prima                     
                 facie case of non-enablement.  We recognize appellants’ argument (Brief, page 7):                        
                         Again, the [e]xaminer appears to set forth an initial burden upon                                
                         [a]ppellants to provide tests as to the applicability of the compounds                           
                         to many of the several embodiments of the claims.  Appellants urge                               
                         that such burden is unfounded in the absence of reasons for doubting                             
                         the objective truth of the statements in the specification on how to                             
                         conduct the methods, explanations why the truth or accuracy of such                              
                         statements are doubted and acceptable evidence or reasoning to                                   
                         back up the assertions that such statements are insufficient.”                                   
                 We again remind the examiner that the burden of proof does not shift to appellant                        
                 until the examiner first meets her burden.  Marzocchi, 439 F.2d at 223-224, 169                          
                 USPQ at 369-370.  In our opinion, the examiner has not met her burden on this                            
                 record.                                                                                                  










Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  Next 

Last modified: November 3, 2007